Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders (MAN-BIOPSY)

Medical University of Vienna

Status and phase

Completed

Phase 4

Conditions

Anxiety Disorder

Major Depressive Disorder (MDD)

Treatments

Drug: Escitalopram

Study type

Interventional

Funder types

Other

Identifiers

NCT01477203

FA103FC001

2011-004860-31 (EudraCT Number)

Details and patient eligibility

About

MAN-BIOPSY pursues the concrete research question whether novel biological and psycho-physiological clusters or categories can be defined to improve treatment and minimize side effects in psychiatry, based on a synopsis of physiological, behavioural, genetic and endocrinological parameters. One major aspect of our research approach is its focuses on the identification of dysfunctions in fundamental information processing mechanisms and neurocomputational mechanisms, and is not restricted to symptom-oriented tasks.

The main objectives of MAN-BIOPSY are therefore

to identify biological and psycho-physiological parameters for major depressive disorders and anxiety disorders, and
to identify predictive markers for treatment response and type/severity of side effects for these disorders.

Enrollment

289 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for patients:

DSM-IV-TR diagnosis of MDD or an anxiety disorder (excluding PTSD, specific phobias, and bipolar disorder) by a structured clinical interview (SCID)
aged 18 to 50 years
drug-free within the last three months prior inclusion
willingness and competence to sign the informed consent form

Inclusion Criteria for remitted subjects:

a previous DSM-IV-TR diagnosis of MDD or an anxiety disorder (excluding PTSD, specific phobias, and bipolar disorder) but no symptoms at present, determined by SCID
aged 18-50 years
drug-free within the last three months prior inclusion
willingness and competence to sign the informed consent form

Inclusion Criteria for healthy control subjects:

Inclusion criteria for healthy control subjects are
willingness and competence to sign the informed consent form
aged 18-50 years
drug-free

Exclusion Criteria:

concomitant major internal or neurological illness
concomitant psychiatric disorders (except depression and anxiety for patients, excluding PTSD, claustrophobia and bipolar disorder)
ingestion of any antipsychotic, antidepressant, or anti-anxiety agent within the last three months prior to the screening visit
current substance abuse
failure to comply with the study protocol or to follow the instructions of the investigating team